Harbin Pharmaceutical vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Harbin Pharmaceutical Group Co Ltd (600664.CG)

Q3 202615 Jul – 26 Aug 2026

▲4

Harbin Pharma Surges on Drug List Inclusion, Strong Earnings, and Procurement Wins

National Essential Medicines List Inclusion Drives Demand 118 product specifications, including six new varieties, were added to China's 2026 National Essential Medicines List. This boosts sales visibility and demand for Harbin Pharmaceutical's drugs, pushing the stock up as investors expect higher volumes and revenue.
This regulatory catalyst directly increases demand for the company's products and was a key driver of the stock's rally.
Strong First-Half Profit Growth Confirmed Harbin Pharmaceutical reported interim net profit of 410 million yuan, up 57.99% year on year, with improved gross margin and return on equity. The profit surge confirms operational strength, attracting investors and supporting the share price.
Earnings growth is a fundamental driver that validates the stock's upward momentum and boosts investor confidence.
Centralized Procurement Wins to Lift Sales Harbin Pharmaceutical's products were proposed for selection in China's 12th round of national centralized drug procurement. Winning bids typically guarantee large-volume sales, which should increase revenue and support the stock price.
Procurement wins provide a concrete demand boost and were highlighted as a positive signal for the company.
New API Approval Adds Product Portfolio Harbin Pharmaceutical's subsidiary received marketing approval for potassium sulfate API from the NMPA. While the financial impact is small, it expands the company's product offerings and reinforces its growth pipeline, contributing to positive sentiment.
This regulatory approval is a new development that adds to the company's product range and supports its growth narrative.

August 202615 Jul – 26 Aug 2026

▲4

Harbin Pharma Surges on Drug List Inclusion, Strong Earnings, and Procurement Wins

National Essential Medicines List Inclusion Drives Demand 118 product specifications, including six new varieties, were added to China's 2026 National Essential Medicines List. This boosts sales visibility and demand for Harbin Pharmaceutical's drugs, pushing the stock up as investors expect higher volumes and revenue.
This regulatory catalyst directly increases demand for the company's products and was a key driver of the stock's rally.
Strong First-Half Profit Growth Confirmed Harbin Pharmaceutical reported interim net profit of 410 million yuan, up 57.99% year on year, with improved gross margin and return on equity. The profit surge confirms operational strength, attracting investors and supporting the share price.
Earnings growth is a fundamental driver that validates the stock's upward momentum and boosts investor confidence.
Centralized Procurement Wins to Lift Sales Harbin Pharmaceutical's products were proposed for selection in China's 12th round of national centralized drug procurement. Winning bids typically guarantee large-volume sales, which should increase revenue and support the stock price.
Procurement wins provide a concrete demand boost and were highlighted as a positive signal for the company.
New API Approval Adds Product Portfolio Harbin Pharmaceutical's subsidiary received marketing approval for potassium sulfate API from the NMPA. While the financial impact is small, it expands the company's product offerings and reinforces its growth pipeline, contributing to positive sentiment.
This regulatory approval is a new development that adds to the company's product range and supports its growth narrative.

Latest15 Jul – 26 Aug 2026

▲4

Harbin Pharma Surges on Drug List Inclusion, Strong Earnings, and Procurement Wins

National Essential Medicines List Inclusion Drives Demand 118 product specifications, including six new varieties, were added to China's 2026 National Essential Medicines List. This boosts sales visibility and demand for Harbin Pharmaceutical's drugs, pushing the stock up as investors expect higher volumes and revenue.
This regulatory catalyst directly increases demand for the company's products and was a key driver of the stock's rally.
Strong First-Half Profit Growth Confirmed Harbin Pharmaceutical reported interim net profit of 410 million yuan, up 57.99% year on year, with improved gross margin and return on equity. The profit surge confirms operational strength, attracting investors and supporting the share price.
Earnings growth is a fundamental driver that validates the stock's upward momentum and boosts investor confidence.
Centralized Procurement Wins to Lift Sales Harbin Pharmaceutical's products were proposed for selection in China's 12th round of national centralized drug procurement. Winning bids typically guarantee large-volume sales, which should increase revenue and support the stock price.
Procurement wins provide a concrete demand boost and were highlighted as a positive signal for the company.
New API Approval Adds Product Portfolio Harbin Pharmaceutical's subsidiary received marketing approval for potassium sulfate API from the NMPA. While the financial impact is small, it expands the company's product offerings and reinforces its growth pipeline, contributing to positive sentiment.
This regulatory approval is a new development that adds to the company's product range and supports its growth narrative.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.